Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 4/20 | 0.45 |
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529117 | 0.80 | GSK3B (0.60) | GSK3BCA12CA1CA9CASP3 | |
| Sulfuric Acid SCHEMBL5520060 | 0.76 | GSK3B (0.56) | GSK3BCA12CA1CA9CASP3 | |
| SCHEMBL1290955 | 0.76 | CHEK1 (0.48) | CA12CA1CA9TGM2CES1 | |
| SCHEMBL29465938 | 0.75 | PTPRC (0.63) | ALDH1A1 | |
| SCHEMBL22336061 | 0.75 | PTPRC (0.63) | ALDH1A1 | |
| SCHEMBL22007092 | 0.75 | PTPRC (0.63) | CA12CA1CA9ALDH1A1 | |
| SCHEMBL5846227 | 0.75 | GPR119 (0.53) | CA12CA1CA9BRD4CREBBP | |
| SCHEMBL2547584 | 0.75 | SMYD3 (0.53) | CA12CA1CA9BRD4CREBBP | |
| SCHEMBL25319400 | 0.74 | BRD4 (0.44) | CA12CA1CA9CASP3ALDH1A1 | |
| SCHEMBL1322162 | 0.74 | MAPT (0.51) | CA12CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| EP-0369344-B1 | N-arylation of isatins | ABBOTT LAB (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0369344-A1 | N-arylation of isatins | ABBOTT LABORATORIES (US) | 1990-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | GSK3B 713/4885CA12 3219/4885CA1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.